MapLight Therapeutics, Inc. (NasdaqGS: MPLT)
Health Care · Biotechnology · US
$7.70
-12.80% today · -58.0% 1Y
MapLight Therapeutics, Inc. (NasdaqGS: MPLT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $427.93M and employs 133 people.
Over the last twelve months the share price has lost 58.0%, trading between 7.46 and 40.43.
Tweenvest scores MapLight Therapeutics, Inc. across four factors: quality 44/100, value 59/100. Its strongest factor is value.
MPLT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $427.93M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -7.42
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $40.43
- 52-week low
- $7.46
- Avg volume (3M)
- —
- Shares outstanding
- 55.58M
- Employees
- 133
- Next earnings
- —
About MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
- ISIN
- US56565P1030
- Founded
- 2018
- Listed since
- Oct 24, 2025
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Allogene Therapeutics, Inc.NasdaqGS: ALLO | $431.86M | $1.25 | -6.02% |
| Assembly Biosciences, Inc.NasdaqGS: ASMB | $431.44M | $21.19 | +5.11% |
| ACRO Biomedical Co., Ltd.TPEX: 6748 | $429.72M | NT$194.50 | -8.69% |
| Prothena Corporation plcNasdaqGS: PRTA | $428.66M | $8.35 | -5.54% |
| Ovid Therapeutics Inc.NasdaqCM: OVID | $421.84M | $2.16 | -8.86% |
| YD Bio LimitedNasdaqGM: YDES | $419.32M | $5.92 | -12.04% |
| Edding Genor Group Holdings LimitedSEHK: 6998 | $418.87M | HK$1.65 | -3.24% |
| Beijing Kawin Technology Share-Holding Co., Ltd.SHSE: 688687 | $412.63M | CN¥16.49 | -10.04% |
Figures last refreshed Oct 18, 2026.